Replies to post #137112 on Biotech Values

[DewDiligence]

The Copaxone language in Teva’s 20-F filing is somewhat different from the bluster you hear from executives on investor presentations. The 20-F says:

http://www.sec.gov/Archives/edgar/data/818686/000119312512067417/d300203d20f.htm

…our patents on Copaxone have been challenged, and we may face generic competition prior to 2014, when the U.S. Orange Book patents covering Copaxone would otherwise expire.

On investor CC’s, Teva’s executives say that there’s no chance in hell this can occur.